TIDMAGY
Allergy Therapeutics PLC
29 May 2018
Allergy Therapeutics plc
("Allergy Therapeutics", the "Group" or "Company")
Positive new clinical data with house-dust mite
immunotherapy
House-dust mite immunotherapy shown to be well-tolerated and
demonstrates highly significant symptom improvement
Allergy experts present an overview of adjuvants at satellite
symposium during EAACI 2018
29 May 2018 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, today announces positive new data on its wholly-owned
modified house-dust mite subcutaneous immunotherapy(1) . This data
will be presented today at the 37(th) Annual Congress of the
European Academy of Allergy and Clinical Immunology (EAACI) in
Munich, Germany.
The Group's modified house-dust mite product sold as through a
Named Patient Program in Spain, is the precursor to the modified
house-dust mite + MPL product currently in Phase I, as announced in
February 2017.
In this observational study conducted in 10 sites across Spain,
141 patients were evaluated and demonstrated a 43% decrease in
combined symptom medication score compared with baseline after one
year (p = <0.0001). In addition, in a subgroup of asthmatic
subjects, 16.7% of patients were observed with moderate persistent
asthma at one year compared with 50.9% at baseline (p = <0.01).
No patients presented with serious adverse events and no patients
had to stop treatment due to any adverse event.
Allergy Therapeutics also presented a series of poster
presentations at EAACI with key highlights including an overview of
the early-phase pre-clinical developments for the Group's planned
recombinant peanut vaccine(3) and a discussion of the results of a
non-interventional study investigating rapid up-dosing of tree
sublingual immunotherapy(4) .
Other events held by the Group at EAACI included a satellite
symposium entitled: "Adjuvants through the ages"(2) which provided
a summary of how adjuvant technologies have evolved and how Allergy
Therapeutics is spearheading the design and testing of state of the
art allergen-specific immunotherapies.
Manuel Llobet, Chief Executive Officer, commented: "We are
excited to be sharing our latest research at EAACI, demonstrating
the breadth of our unique allergen immunotherapy company. The
positive new data on our modified house-dust mite immunotherapy and
our recent announcement on the success of our Grass G205
dose-finding clinical study confirms that our novel
allergen-specific immunotherapies are formulated to the optimal
strength, and we believe Allergy Therapeutics has the potential to
transform allergy treatment with optimised-dose,
well-characterised, aluminium-free, convenient products."
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
About the modified mite MPL programme
House dust mite is the major cause of perennial allergic
rhinitis and allergic asthma(6) . The modified house-dust mite +
MPL product builds on the strong foundation of technologies
employed in the successful Pollinex Quattro range of allergy
immunotherapies. It is the only house-dust mite immunotherapy
utilising MCT(R) (Microcrystalline Tyrosine), a natural,
biodegradable depot, and the adjuvant MPL for the treatment of
perennial allergic rhinitis which makes this vaccine unique in the
$1.5 billion per year market(7) . The modified house-dust mite +
MPL product is currently in phase I with an anticipated readout in
Q1 2019. This is an exciting opportunity for the group to boost its
addressable market.
About the Annual Congress of the European Academy of Allergy and
Clinical Immunology (EAACI)
The EAACI Congress 2018 is a congress organised by the European
Academy of Allergy and Clinical Immunology (EAACI) which offers a
unique opportunity to learn about new discoveries and exchange
experience with professionals in the field of allergy and clinical
immunology. The Congress is taking place in Munich, Germany from
26-30 May 2018.
References
(1) A. Roger et al., Immunological and clinical changes after
1-year treatment with a tyrosine-adsorbed mite allergoid:
preliminary results. EAACI 2018. PDS 30, Poster Discussion Zone 3.
29(th) May 2018 - 15:30-17:00
(2) Allergy Therapeutics Symposium. EAACI 2018. Adjuvants
through the ages. Hall 13a, 27 May 2018, 17:30-19:00.
(3) M. F. Bachmann et al., Development of a recombinant vaccine
based on virus-like particles for the treatment of peanut allergy.
EAACI 2018. OAS 31, Hall 5. 29(th) May 2018 - 15:30-17:00
(4) N. Y. Breitruck et al., Rapid up-dosing in sublingual
specific immunotherapy is well-tolerated and effective in patients
suffering from tree pollen allergic rhinitis. EAACI 2018. TPS 16,
Poster Area. 27(th) May 2018 - 12:00-13:30
(5)
http://otp.investis.com/clients/uk/allergy_therapeutics/rns/regulatory-story.aspx?newsid=1021128&cid=1045
(6) Calderón M et al., Respiratory allergy caused by house dust
mites: What do we really know? J Allergy Clin Immunol. 2015
Jul;136(1):38-48
(7) QYR Pharma report. September 2016
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGUWCAUPRGBR
(END) Dow Jones Newswires
May 29, 2018 02:01 ET (06:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024